Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease

Locatelli, Elyana; Acuna, Kelly; Betz, Jason; Tovar, Arianna

doi:10.1097/ico.0000000000003266

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical lifitegrast, a lymphocyte function-associated antigen 1 antagonist, may offer patients benefits from 14 days after treatment initiation, although this benefit may take up to 84 days to manifest 45. Prolonged treatment with lifitegrast has been shown to be safe, and a recent retrospective cohort study comparing lifitegrast with ciclosporin demonstrated similar effectiveness for dry eye disease treatment 4647…”

Section: Treatment Of Specific Causesmentioning

confidence: 99%

Dry eye disease management

Safir,

Twig,

Mimouni

2024

BMJ

View full text Add to dashboard Cite

Section: Treatment Of Specific Causesmentioning

confidence: 99%

Dry eye disease management

Safir,

Twig,

Mimouni

2024

BMJ

View full text Add to dashboard Cite

“…Cyclosporine 0.05% and 0.09%, trialed in adults with DED based on questionnaire scores and clinical features, most robustly increased tear production and less robustly, but still significantly, reduced DED-related symptoms compared to placebo across various trials [ 14 – 18 ]. Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist whose anti-inflammatory mechanism of action comes from blocking the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1) [ 19 ]. In clinical trials, lifitegrast 5% improved both eye dryness scores and ocular surface signs, including tear production and corneal staining, from baseline compared to vehicle [ 20 – 22 ].…”

Section: Dry Eye Disease Sourcesmentioning

confidence: 99%

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

Valdés-Arias,

Locatelli,

Sepulveda-Beltran

et al. 2024

Drugs

Self Cite

View full text Add to dashboard Cite

Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and neurosensory abnormalities. Individuals with DED may exhibit a range of clinical signs, including tear instability, reduced tear production, and epithelial disruption, that are driven by different pathophysiological contributors. Those affected often report a spectrum of pain and visual symptoms that can impact physical and mental aspects of health, placing an overall burden on an individual’s well-being. This cumulative impact of DED on an individual’s activities and on society underscores the importance of finding diverse and effective management strategies. Such management strategies necessitate an understanding of the underlying pathophysiological mechanisms that contribute to DED in the individual patient. Presently, the majority of approved therapies for DED address T cell-mediated inflammation, with their tolerability and effectiveness varying across different studies. However, there is an emergence of treatments that target additional aspects of the disease, including novel inflammatory pathways, abnormalities of the eyelid margin, and neuronal function. These developments may allow for a more nuanced and precise management strategy for DED. This review highlights the recent pharmacological advancements in DED therapy in the United States. It discusses the mechanisms of action of these new treatments, presents key findings from clinical trials, discusses their current stage of development, and explores their potential applicability to different sub-types of DED. By providing a comprehensive overview of products in development, this review aims to contribute valuable insights to the ongoing efforts in enhancing the therapeutic options available to individuals suffering from DED.

show abstract

“…Locatelli et al in a 2023 review of sixty-four individuals [21] concluded that more patients preferred Cyclosporin A over Lifitegrast. Other available treatment modalities also include interventional procedures such as punctual plug occlusion which are often performed to prevent tear drainage.…”

Section: Patient Management and Treatment Modalities -The Old And The...mentioning

confidence: 99%

focus on Sjogren’s Dry Eye Disease - pathogenesis, patient management, and new advancements in therapy

Uram,

Bogacz,

Gaik

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Sjogren’s syndrome (SS) is a systemic chronic inflammatory autoimmune disease of unknown etiology that primarily affects exocrine glands. Most commonly Sjogren’s syndrome presents with dryness of the mouth and eyes, but it can also affect major organs and systems of the body and increase the risk of non-Hodgkin lymphoma. Due to non-specific symptoms that pose diagnostic challenges and a lack of standardized screening tools and classification criteria, the global incidence and prevalence of the disease are hard to evaluate. Studies estimate that Sjogren’s syndrome affects between 400,000 to 3.1 million adults worldwide and most likely is a condition significantly underdiagnosed. Aim of the study: Review of current knowledge about Sjogren’s dry eye disease, underlying pathologies, diagnostic problems, and current treatment options with a focus on the most recent advancements in therapy. Methods and materials: A review of chosen literature in the PubMed database, MDPI database, and GoogleScholar in the years 2000-2023 was conducted using the following keywords: “Sjogren’s syndrome”, “Sjogren’s syndrome ophthalmology”, “Sjogren’s dry eye syndrome”, “Sjogren’s syndrome associated dry eye”, “Lymphoma in Sjogren’s syndrome”, “Diagnosing Sjogren’s syndrome dry eye”, “Sjogren’s syndrome epidemiology”. Results: Sjogren’s syndrome is a far from rare autoimmune disease that affects many organs of the body and can significantly lower quality of life and increase mortality and morbidity. Due to its surreptitious symptom onset, Sjogren’s syndrome is commonly underdiagnosed. New diagnostic and treatment modalities for Sjogren’s syndrome dry eye are on the horizon. Conclusions: Standardized, internationally recognized criteria and a high level of clinical suspiciousness are needed for a timely and accurate diagnosis of Sjogren’s syndrome. Quick diagnosis is a significant facilitating factor for maintaining a high quality of life in Sjogren’s syndrome dry eye.

show abstract

Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease

Cited by 7 publications

References 25 publications

Dry eye disease management

Dry eye disease management

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

focus on Sjogren’s Dry Eye Disease - pathogenesis, patient management, and new advancements in therapy

Contact Info

Product

Resources

About